Brief: Aeterna Zentaris Announces Notice Of Allowance For U.S. Patent Covering AEZS-150 For The Potential Treatment Of Chronic Hypoparathyroidism
02/03/2022 13:29
March 2 (Reuters) - Aeterna Zentaris Inc AEZS.TO :
* AETERNA ZENTARIS ANNOUNCES NOTICE OF ALLOWANCE FOR U.S.
PATENT
COVERING AEZS-150 FOR THE POTENTIAL TREATMENT OF CHRONIC
HYPOPARATHYROIDISM
Source text for Eikon: ID:nGNX1CFhSy
Further company coverage: AEZS.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on COSCIENS Biopharma
See all newsBrief: COSCIENS Acquires Nualtis Corp
Refile: Canada's COSCIENS Biopharma Q2 net loss narrows on higher sales
Canada's COSCIENS Biopharma Q1 net income turns positive on discontinued German operations
Brief: Cosciens Biopharma Inc Not Aware Of Material Undisclosed Information Amid Recent Trading Activity
Brief: Cosciens Provides Strategic Update